Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 112

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 112
---
ual basis taxpayer may elect to apply the same rules applicable to cash basis taxpayers with respect
to the sale of ADRs that are traded on an established securities market, provided that the election must be applied consistently from
year to year and cannot be changed without the consent of the IRS. For an accrual method taxpayer who does not make such an election,
units of foreign currency received will generally be translated into United States dollars at the spot rate on the trade date of the sale.
Such an accrual basis taxpayer may recognize foreign currency exchange gain or loss based on currency fluctuations between the trade date
and the settlement date of such sale. In general, any such gain or loss will be ordinary and will be treated as from sources within the
United States for United States foreign tax credit purposes.

| 72 |

<div align='center'>SELLING SHAREHOLDER</div>

This prospectus relates to the possible resale from time to time by
the Selling Shareholder of any or all of the Ordinary Shares (represented by Depositary Shares) that may be issued by us to the Selling
Shareholder under the Purchase Agreement. Such shares of include (i) up to 33,413,549 Purchase Shares that we may elect, in our sole discretion,
to issue and sell to the Selling Shareholder, from time to time from and after the Commencement Date under the Purchase Agreement; and
(ii) up to 721,651 Commitment Shares that may be issued to the Selling Shareholder in connection with related issuances and sales of Purchase
Shares to release the Company of its liability to pay the Commitment Fee as consideration for the Selling Shareholder’s execution
and delivery of the Purchase Agreement.

As used in this prospectus,
the term “Selling Shareholder” includes the Selling Shareholder listed in the table below, and its permitted pledgees,
donees, transferees, assignees, successors, designees, successors-in-interest and others who later come to hold any of the Selling Shareholder’s
interest in the securities in accordance with the terms of the applicable agreements governing their respective registration rights, other
than through a public sale. This prospectus also covers any additional securities that may become issuable by reason of stock splits,
stock dividends or other similar transactions.

For additional information
regarding the issuance of the securities covered by this prospectus, see the section entitled “Committed Equity Financing”
above. We are registering the securities pursuant to the provisions of the Purchase Agreement and the Registration Rights Agreement in
order to